Daniel v. WYETH PHARMACEUTICALS, INC.
32 A.3d 1260
CourtSupreme Court of Pennsylvania
DecidedDecember 5, 2011
Docket318 EAL 2011, 19 EAL 2011
StatusPublished
Cited by1 cases
This text of 32 A.3d 1260 (Daniel v. WYETH PHARMACEUTICALS, INC.) is published on Counsel Stack Legal Research, covering Supreme Court of Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Bluebook
Daniel v. WYETH PHARMACEUTICALS, INC., 32 A.3d 1260 (Pa. 2011).
Opinion
ORDER
AND NOW, this 5th day of December, 2011, the Petition for Allowance of Appeal is GRANTED, LIMITED TO the issue set forth below. Allocatur is DENIED as to all remaining issues. The issue, as stated by Petitioner, is:
Whether the Superior Court erred in reversing the trial court’s grant of JNOV for Wyeth on [Respondents’] punitive damages claim under Pennsylvania law, where (a) the FDA extensively reviewed and approved the prescription drug at issue, the sufficiency of the testing for that drug, and the drug’s label warnings of the risk of breast cancer, (b) there was no evidence that Wyeth concealed information from or misled the FDA or knew that the risk of breast cancer was greater than disclosed in its warnings, and (c) the drug was extensively tested and studied by Wyeth and independent researchers?
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Fecho v. Eli Lilly & Co.
914 F. Supp. 2d 130 (D. Massachusetts, 2012)
Cite This Page — Counsel Stack
Bluebook (online)
32 A.3d 1260, Counsel Stack Legal Research, https://law.counselstack.com/opinion/daniel-v-wyeth-pharmaceuticals-inc-pa-2011.